254 related articles for article (PubMed ID: 10520859)
21. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
22. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
[TBL] [Abstract][Full Text] [Related]
23. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
24. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
25. [Conjugated bile acid profiles in serum, urine, and bile of patients with primary biliary cirrhosis under the ursodeoxycholic acid treatment].
Aoshima M; Nakamura K; Makino I
Hokkaido Igaku Zasshi; 1995 Jan; 70(1):57-67. PubMed ID: 7744371
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
[TBL] [Abstract][Full Text] [Related]
28. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
Papatheodoridis GV; Hadziyannis ES; Deutsch M; Hadziyannis SJ
Am J Gastroenterol; 2002 Aug; 97(8):2063-70. PubMed ID: 12190178
[TBL] [Abstract][Full Text] [Related]
29. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis.
Wong F; Liu P; Lilly L; Bomzon A; Blendis L
Clin Sci (Lond); 1999 Sep; 97(3):259-67. PubMed ID: 10464050
[TBL] [Abstract][Full Text] [Related]
30. Two successive pregnancies after ursodeoxycholic acid therapy in a previously infertile woman with antimitochondrial antibody-negative primary biliary cirrhosis.
Korkut E; Kisacik B; Akcan Y; Belenli O; Bicik Z; Yucel O
Fertil Steril; 2005 Mar; 83(3):761-3. PubMed ID: 15749512
[TBL] [Abstract][Full Text] [Related]
31. [Somatostatin and ventricular function in liver cirrhosis].
de la Villa FM; Solano López D; Bóveda J; Urrengoetxea J; Martínez Odriozola P; Bilbao Goitia P; Franco Vicario R
Rev Clin Esp; 1990 Feb; 186(2):58-62. PubMed ID: 1970439
[TBL] [Abstract][Full Text] [Related]
32. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
33. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
Huet PM; Vincent C; Deslaurier J; Coté J; Matsutami S; Boileau R; Huet-van Kerckvoorde J
Gastroenterology; 2008 Nov; 135(5):1552-60. PubMed ID: 18722374
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis.
Dimoulios P; Kolios G; Notas G; Matrella E; Xidakis C; Koulentaki M; Tsagarakis N; Kouroumalis A; Kouroumalis E
Aliment Pharmacol Ther; 2005 Feb; 21(3):227-34. PubMed ID: 15691296
[TBL] [Abstract][Full Text] [Related]
35. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
36. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
[TBL] [Abstract][Full Text] [Related]
37. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
Jorgensen R; Angulo P; Dickson ER; Lindor KD
Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurova FKh
Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
[TBL] [Abstract][Full Text] [Related]
40. Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites.
Wong F; Bomzon A; Allard J; Liu P; Blendis L
Clin Sci (Lond); 1999 May; 96(5):467-74. PubMed ID: 10209078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
